Antiviral therapy for coronavirus disease 2019.
10.11817/j.issn.1672-7347.2020.200211
- Author:
Subo GONG
1
;
Jing SU
2
;
Xianghong YAN
3
;
Fang LI
2
;
Lang HU
2
;
Shaokun LIU
4
Author Information
1. Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha 410011. gsb510@csu.edu.cn.
2. Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha 410011.
3. Department of Laboratory Medicine, Changsha Central Hospital, Nanhua University, Changsha 410004.
4. Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China. shaokunliu228@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
antiviral drugs;
coronavirus disease 2019;
severe acute respiratory syndrome coronavirus 2
- MeSH:
Antiviral Agents;
therapeutic use;
Betacoronavirus;
China;
Coronavirus Infections;
drug therapy;
Humans;
Pandemics;
Pneumonia, Viral;
drug therapy;
Practice Guidelines as Topic
- From:
Journal of Central South University(Medical Sciences)
2020;45(5):598-602
- CountryChina
- Language:English
-
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the outbreak of coronavirus disease 2019 in Wuhan City, China. The SARS-CoV-2 is genetically similar to the coronavirus derived from bat. The SARS-CoV-2, the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV) all belong to beta coronavirus. Since the outbreak of the coronavirus disease 2019, effective antiviral drugs have become a hot issue in the world. Very little about SARS-CoV-2 is known and there is no precedent for treatment. The National Health Commission has repeatedly revised the diagnosis and treatment guide for the coronavirus disease 2019. The latest guide is "New Coronary Virus-Infected Pneumonia Diagnosis and Treatment Plan (Seventh Trial Version)"(short for Seventh Version of Diagnosis and Treatment Plan). But the use of antiviral drugs is still on trial and no rigorous clinical trials data is available. Hot anti-SARS-CoV-2 drugs include interferon α, ribavirin, lopinavir/ritonavir, chloroquine phosphate, abidol, as well as hydroxychloroquine sulfate and remdesivir. But the later 2 drugs aren't mentioned in the Seventh Version of Diagnosis and Treatment Plan.
